Achieve Life Sciences (ACHV)

Cytisinicline is a naturally occurring plant-based alkaloid that interacts with nicotinic acetylcholine receptors, the same receptor system involved in nicotine dependence. The aim is to reduce withdrawal symptoms and cravings, helping users quit combustible cigarettes or nicotine vaping products. Smoking cessation has long been a challenging treatment area, with existing prescription and over-the-counter options often limited by tolerability, adherence, or relapse rates. Achieve is seeking to position cytisinicline as a differentiated therapy if it can secure regulatory approval.

The company has advanced cytisinicline through late-stage clinical development for cigarette smoking cessation and has also completed a Phase 2 study in vaping cessation. It has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration for a potential vaping-related indication, an area where approved pharmaceutical treatment options are limited. Achieve’s operations span Canada, the United States, and the United Kingdom, reflecting its clinical and corporate footprint. For investors, the key considerations include trial results, FDA requirements, funding needs, intellectual property, manufacturing readiness, and the potential market for a prescription therapy targeting nicotine addiction.